Jane Street’s Astria Therapeutics ATXS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-173,511
Closed -$2.27M 11538
2025
Q4
$2.27M Sell
173,511
-45,813
-21% -$547K ﹤0.01% 4569
2025
Q3
$1.6M Buy
219,324
+145,080
+195% +$982K ﹤0.01% 5354
2025
Q2
$398K Sell
74,244
-34,654
-32% -$168K ﹤0.01% 7353
2025
Q1
$582K Buy
108,898
+82,805
+317% +$579K ﹤0.01% 6584
2024
Q4
$233K Sell
26,093
-10,643
-29% -$113K ﹤0.01% 8151
2024
Q3
$404K Sell
36,736
-90,644
-71% -$1.01M ﹤0.01% 7546
2024
Q2
$1.16M Buy
127,380
+93,550
+277% +$913K ﹤0.01% 5497
2024
Q1
$476K Sell
33,830
-6,247
-16% -$77.8K ﹤0.01% 6765
2023
Q4
$308K Buy
+40,077
New +$222K ﹤0.01% 7564
2023
Q3
Sell
-10,751
Closed -$89.6K 8602
2023
Q2
$89.6K Sell
10,751
-91,084
-89% -$1.05M ﹤0.01% 8048
2023
Q1
$1.35M Buy
101,835
+90,840
+826% +$1.23M ﹤0.01% 4466
2022
Q4
$164K Sell
10,995
-10,503
-49% -$108K ﹤0.01% 7812
2022
Q3
$194K Buy
+21,498
New +$144K ﹤0.01% 8205
2021
Q3
Sell
-4,583
Closed -$58K 9892
2021
Q2
$58K Buy
+4,583
New +$59.5K ﹤0.01% 9467
2021
Q1
Sell
-10,167
Closed -$131K 9064
2020
Q4
$131K Buy
+10,167
New +$181K ﹤0.01% 7121
2020
Q3
Sell
-2,277
Closed -$88K 7120
2020
Q2
$88K Buy
+2,277
New +$81.1K ﹤0.01% 6756
2020
Q1
Sell
-2,456
Closed -$87K 5272
2019
Q4
$87K Buy
+2,456
New +$77.4K ﹤0.01% 4864
2018
Q3
Sell
-387
Closed -$22K 5059
2018
Q2
$22K Buy
+387
New +$35.7K ﹤0.01% 4861
2017
Q4
Sell
-195
Closed -$25K 4540
2017
Q3
$25K Buy
+195
New +$16.3K ﹤0.01% 4349

Jane Street's ATXS Position: Q1 2026 in Review

Jane Street sold out of Astria Therapeutics (ATXS) in Q1 2026, closing a stake of 173,511 shares — an estimated $2.27M sold.

Jane Street first reported a position in ATXS in Q3 2017 and held it in 19 quarters. The position peaked at $2.27M in Q4 2025. 0 funds tracked by Wall St. Rank hold ATXS as of Q1 2026.

  • Jane Street reported no remaining Astria Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Jane Street sold 173,511 Astria Therapeutics shares in Q1 2026, an estimated $2.27M.
  • Jane Street first reported a position in Astria Therapeutics in Q3 2017 and held it in 19 quarters.
  • Jane Street's Astria Therapeutics position peaked at $2.27M in Q4 2025.
  • 0 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.